H.C. Wainwright Reiterates Buy Rating on Actuate Therapeutics (ACTU)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- US stock futures muted as oil holds near April highs ahead of Fed decision
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
| ACTUATE (NASDAQ: ACTU) | Delayed: 0.53 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.53 | 52 Week High | $6.07 | |||
| Open | $0.53 | 52 Week Low | $3.89 | |||
| Day High | $0.53 | P/E | 3.53 | |||
| Day Low | $0.53 | EPS | $0.15 | |||
| Volume | 1,118 | |||||
